Since early 2022, ADCGEN has been committed to identifying and advancing novel therapeutic targets in the fight against cancer. Our progress is driven by a powerful AI-enabled discovery platform, built in close collaboration with our scientific experts and advisors.
ADCGEN-04 is a first-in-class Antibody-Drug Conjugate (ADC) designed to treat a range of solid tumors by targeting a novel, previously unexplored antigen with no known direct competition.
This therapeutic candidate integrates a high-affinity monoclonal antibody (mAb) with a powerful cytotoxic payload, connected via a tumor-selective, cleavable linker that ensures targeted delivery and minimal off-target effects.
A pre-licensing agreement for ADCGEN-04 has been signed with a U.S.-based biopharmaceutical company, reflecting early validation and commercial interest.
CA09 is a next-generation TEAD inhibitor targeting a critical oncogenic pathway frequently activated in cancer. TEAD, a transcription factor overexpressed in multiple tumor types, is central to YAP/TAZ-mediated signaling, promoting tumor growth and survival.
CA09 uniquely employs a dual mechanism of action, leveraging both orthosteric and allosteric inhibition through distinct small molecules to achieve robust suppression of the YAP/TAZ pathway.
Preclinical development has revealed no significant safety concerns, supporting its continued advancement toward clinical trials. While multiple players are exploring the TEAD landscape, CA09 stands out through its biomarker-driven approach, enabling precision targeting of tumors with specific genomic alterations.
With a lead focus on Head & Neck and Breast Cancers, and potential expansion across a range of epithelial tumors, CA09 is well-positioned to become a differentiated TEAD inhibitor with global market potential in precision oncology.
CA11-SM is a highly specific PARP1 inhibitor targeting a well-known and validated oncogenic pathway. As a PARP1-specific inhibitor, it disrupts DNA repair mechanisms in cancer cells, leading to tumor cell death.
While the PARP1 target is well-established, its complex nature and the availability of limited resources have resulted in only two development campaigns.
Currently, competition in the PARP1 inhibitor space is limited but expected to grow rapidly, necessitating continuous monitoring of emerging competitors.
Differentiation remains a key challenge, as the best strategy to distinguish PARP inhibitors is still unclear.
Identifying predictive biomarkers will be crucial for patient selection and optimizing clinical success.
CA11-SM is designed to treat various epithelial tumors, offering broad application across multiple oncology indications. With full intellectual property rights secured, the compound holds strong commercial potential in a rapidly expanding global market.
The rapid growth of the internal pipeline demonstrates the great drug discovery capabilities driven by the use of our AI platform. Likewise, our partners and collaborators take advantage of our technology and high scientific knowledge to increase and accelerate their initiatives for the discovery and development of new drugs against cancer.
We combine our expertise in biology and AI to identify new therapeutic targets.